Panagene Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
4,216
5,011
5,920
6,961
7,395
Cost of Goods Sold (COGS) incl. D&A
2,333
3,013
2,602
3,248
4,628
Gross Income
1,883
1,999
3,318
3,713
2,766
SG&A Expense
5,412
4,252
3,140
4,435
5,630
EBIT
3,556
-
157
749
2,895
Unusual Expense
-
747
189
43
3,285
Non Operating Income/Expense
369
155
67
132
322
Interest Expense
1,201
1,214
1,272
982
178
Pretax Income
4,271
2,470
1,171
1,558
6,549
Consolidated Net Income
4,271
2,470
1,171
1,558
6,549
Net Income
4,271
2,470
1,171
1,558
6,549
Net Income After Extraordinaries
3,777
2,745
1,713
1,558
6,549
Net Income Available to Common
4,765
2,195
630
1,558
6,549
EPS (Basic)
184.00
82.00
23.00
55.00
208.00
Basic Shares Outstanding
26
27
27
28
31
EPS (Diluted)
183.71
81.88
23.49
55.31
208.05
Diluted Shares Outstanding
26
27
27
28
31
EBITDA
2,660
1,182
1,178
79
1,191
Other Operating Expense
28
26
21
27
32
Non-Operating Interest Income
117
121
65
84
130

About Panagene

View Profile
Address
54 Techno 10-ro
Daejeon DE 34027
Korea, Republic Of
Employees -
Website http://www.panagene.com
Updated 09/14/2018
PANAGENE Inc. engages in the molecular diagnostics business. It develops, manufactures and sells peptide nucleic acid (PNA) genetic diagnostic chips. The firm operates through the PNA Materials and Diagnostic Product business divisions.